Redeye states that the Q2 report was strong, with solid density improvements resulting in a signific...
Guidance upgrade, but slightly softer comments into H2e EBITA +9% (2% org, 7% FX), expect lower grow...
AcuCorts användarvänliga kortisonfilm ISICORT® har erhållit godkännande från Läkemedelsverket i Sver...
Sales 7% above our expectations… …but adj. EBITA 23% below Management intends to ramp up M&A pace Q...
TCECUR avslutar H1-22 med flaggan i topp där den nyligen presenterade Q2-rapporten visade stark till...
Prostatype Genomics has secured a SEK 22.5m rights issue (pre-cost of some SEK 3.
Q2 EBIT of DKK 52m in line with ABGSCe No shift to JaTak expected – cash cow set to continue New 1Y ...
Volymerna föll sekventiellt från rekordnivåerna i Q1 Med 3 292 fat per dag föll Mahas produktion til...
Marimekko’s Q2 result was strong and broadly in line with expectations.
Dovre’s Q2 profitability topped our estimates mostly thanks to Project Personnel, where demand remai...
Redeye saw sales a bit lower than our expectations for the quarter.
Redeye sees a soft Q2 report from CombinedX hurt mainly by issues we believe will be temporary, such...
Redeye's first comments on the Q2 report this morning.
Redeye comments on Azelio’s Q2 report which financials held no surprises.
Redeye will likely make minor forecast adjustments following Binero’s Q2’22 report, where the revenu...
Redeye concludes that Q2 confirmed Sensys Gatso’s strong streak with good growth in TRaaS and contin...
Redeye notes that Starbreeze Q2 report was stronger than expected.
Redeye comments on Embracers Q1 2022/23 report. Net sales came in 1% higher than our estimates, whil...
Redeye saw a Q2 report showing strong growth and a record high gross margin at 70%.
Calliditas recorded Q2 sales are SEK 64m in Q2 compared with SEK 0m in Q2 2021, and Tarpeyo product ...
